Ciprofloxacin extended-release tablets are indicated only for the treatment of urinary tract infections, including acute uncomplicated pyelonephritis, caused by susceptible strains of the designated microorganisms as listed below.

Ciprofloxacin extended-release tablets and ciprofloxacin immediate-release tablets are not interchangeable.

Please see DOSAGE AND ADMINISTRATION for specific recommendations.Uncomplicated Urinary Tract Infections (Acute Cystitis) caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus Treatment of infections due to this organism in the organ system was studied in fewer than 10 patients..Complicated Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, or Pseudomonas aeruginosa .Acute Uncomplicated Pyelonephritis caused by Escherichia coli.THE SAFETY AND EFFICACY OF CIPROFLOXACIN EXTENDED-RELEASE TABLETS IN TREATING INFECTIONS OTHER THAN URINARY TRACT INFECTIONS HAS NOT BEEN DEMONSTRATED.Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin.

Therapy with ciprofloxacin extended-release tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued.

Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin extended-release tablets and other antibacterial drugs, ciprofloxacin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

---

Urinary tract infection -- Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.

Acute pyelonephritis --

Acute Cystitis --

Infection -- Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.

Communicable Diseases -- broad class of diseases whose causative agents may be passed between individuals in many different ways.

BACTERIAL RESISTANCE --

Ciprofloxacin extended-release tablets are contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antimicrobial agents, or any of the product components.Concomitant administration with tizanidine is contraindicated.

(See PRECAUTIONS: Drug Interactions.)

---

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

THE SAFETY AND EFFECTIVENESS OF CIPROFLOXACIN EXTENDED-RELEASE TABLETS IN PEDIATRIC PATIENTS AND ADOLESCENTS (UNDER THE AGE OF 18 YEARS), PREGNANT WOMEN, AND NURSING WOMEN HAVE NOT BEEN ESTABLISHED.

(See PRECAUTIONS: Pediatric Use, Pregnancy, and Nursing Mothers subsections.) The oral administration of ciprofloxacin caused lameness in immature dogs.

Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage.

Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species.(See ANIMAL PHARMACOLOGY.)

The following US Branded drugs contain Ciprofloxacin

---

CIPRO -- BAYER HEALTHCARE PHARMACEUTICALS INC

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER -- BAYER HEALTHCARE PHARMACEUTICALS INC

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER -- BAYER PHARMACEUTICALS CORP

CIPROFLOXACIN IN DEXTROSE 5% -- HIKMA FARMACEUTICA (PORTUGAL) SA

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- ACS DOBFAR INFO SA

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- BAXTER HEALTHCARE CORP

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- CLARIS LIFESCIENCES LTD

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- HOSPIRA INC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER -- TEVA PARENTERAL MEDICINES INC

CIPRO XR -- BAYER HEALTHCARE PHARMACEUTICALS INC

CIPROFLOXACIN EXTENDED RELEASE -- ANCHEN PHARMACEUTICALS INC

CIPROFLOXACIN EXTENDED RELEASE -- DR REDDYS LABORATORIES LTD

CIPROFLOXACIN EXTENDED RELEASE -- MYLAN PHARMACEUTICALS INC

CIPROFLOXACIN EXTENDED RELEASE -- SANDOZ INC

CIPRODEX -- ALCON INC